2 of the highest-quality blue chip ASX 200 stocks money can buy

Analysts think these blue chips are top buys for investors right now. But why?

| More on:
A businessman lights up the fifth star in a lineup, indicating positive share price for a top performer

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ASX 200 index is home to 200 of the largest listed companies on the Australian share market.

Among these companies are some true blue chip stars that could form the foundations for a winning portfolio.

But which ASX 200 shares could be top buys today? Let's take a look at two true blue chip options for investors. They are as follows:

CSL Limited (ASX: CSL)

The first ASX 200 share that analysts rate as a buy is CSL.

It is one of the world's leading biotherapeutics companies with a collection of industry-leading therapies and vaccines. This includes therapies such as Privigen, Hizentra, Idelvion, and Afstyla.

Combined with its development pipeline, CSL appears well-placed for growth in the coming years. Bell Potter expects this to be the case and is forecasting double digit earnings growth. It said:

Behring is CSL's largest division (72% of revenue) and we expect it will continue to do the heavy lifting in the near-term, both in topline growth and margin expansion.

CSL's FY25 revenue guidance of 5%-7% (BPe 6.5%) is comprised of "high single digit" growth for Behring and "flattish" growth for Seqirus and Vifor. Behring's more favourable outlook, coupled with its gross margin recovery to pre-pandemic levels (which we expect in FY28), results in confidence that CSL will be able to achieve its guidance of "annual double-digit earnings growth" over the mid-term, despite more challenging near-term prospects for Seqirus and Vifor.

Bell Potter currently has a buy rating and $345.00 price target on its shares. This suggests that upside of 20% is possible over the next 12 months.

ResMed Inc. (ASX: RMD)

Another ASX 200 blue chip share that could be a great addition to your portfolio is ResMed.

If you're one of the estimated one in five people with a sleep disorder globally, you might be well aware of ResMed and its products. Though, that said, with the vast majority of sufferers still undiagnosed, perhaps you won't. This gives ResMed a huge growth runway as education and awareness increases.

And while there has been some chatter about how weight loss drugs could impact its growth, Morgans doesn't agree and believes the future remains very bright for the company. It recently said:

While weight loss drugs have grabbed headlines and investor attention, we see these products having little impact on the large, underserved sleep disorder breathing market, and do not view them as category killers. Although quarters are likely to remain volatile, nothing changes our view that the company remains well placed and uniquely positioned as it builds a patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.

Morgans is bullish on ResMed. It currently has an add rating and $41.33 price target on its shares. This implies potential upside of 8.5% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has positions in CSL and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

A young woman sits on a sofa in a stylish home with her laptop computer balanced on her knee and smiles with a satisfied look on her face at what she's seeing on the screen.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These stocks could provide strong passive income.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Blue Chip Shares

3 ASX 200 blue chip shares to buy with $3,000 in July

Analysts have recently named these well-known stocks as top buys.

Read more »

Two people having a meeting using a laptop and tablet to discuss Seven West Media's balance sheet
Blue Chip Shares

3 fantastic ASX shares to buy for an SMSF

Let's see why these shares that brokers rate as buys could be top picks for super investors.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Blue Chip Shares

Buy these fantastic ASX 200 blue chips with $10,000

Analysts think these top stocks are buys right now.

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Blue Chip Shares

The best ASX shares to buy and forget for 10+ years

Want to make long term investments? Here are three picks that brokers rate as buys.

Read more »

An ASX investor in a business shirt and tie looks at his computer screen and scratches his head with one hand wondering if he should buy ASX shares yet
Blue Chip Shares

This popular ASX 200 blue-chip share has literally gone nowhere in 17 years

Even blue-chip shares can fall short.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Blue Chip Shares

3 no-brainer ASX shares to buy now with $5,000

Brokers think these shares could be among the best to buy right now.

Read more »

Broker checking out the share price oh his smartphone and laptop.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These businesses are predicted to pay significant passive income to shareholders.

Read more »